Epidermal Growth Factor Receptor activation promotes ADA3 acetylation through the AKT-p300 pathway

Shashank Srivastava, Shakur Mohibi, Sameer Mirza, Hamid Band, Vimla Band

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The ADA3 (Alteration/Deficiency in Activation 3) protein is an essential adaptor component of several Lysine Acetyltransferase (KAT) complexes involved in chromatin modifications. Previously, we and others have demonstrated a crucial role of ADA3 in cell cycle progression and in maintenance of genomic stability. Recently, we have shown that acetylation of ADA3 is key to its role in cell cycle progression. Here, we demonstrate that AKT activation downstream of Epidermal Growth Factor Receptor (EGFR) family proteins stimulation leads to phosphorylation of p300, which in turn promotes the acetylation of ADA3. Inhibition of upstream receptor tyrosine kinases (RTKs), HER1 (EGFR)/HER2 by lapatinib and the accompanying reduction of phospho-AKT levels led to a decrease in p300 phosphorylation and ADA3 protein levels. The p300/PCAF inhibitor garcinol also destabilized the ADA3 protein in a proteasome-dependent manner and an ADA3 mutant with K→R mutations exhibited a marked increase in half-life, consistent with opposite role of acetylation and ubiquitination of ADA3 on shared lysine residues. ADA3 knockdown led to cell cycle inhibitory effects, as well as apoptosis similar to those induced by lapatinib treatment of HER2+ breast cancer cells, as seen by accumulation of CDK inhibitor p27, reduction in mitotic marker pH3(S10), and a decrease in the S-phase marker PCNA, as well as the appearance of cleaved PARP. Taken together our results reveal a novel RTK-AKT-p300-ADA3 signaling pathway involved in growth factor-induced cell cycle progression.

Original languageEnglish (US)
Pages (from-to)1515-1525
Number of pages11
JournalCell Cycle
Volume16
Issue number16
DOIs
StatePublished - Aug 18 2017

Fingerprint

Acetylation
Epidermal Growth Factor Receptor
Cell Cycle
Phosphorylation
S 10
Cyclin-Dependent Kinase Inhibitor p27
Proteins
Genomic Instability
Ubiquitination
Proliferating Cell Nuclear Antigen
Receptor Protein-Tyrosine Kinases
Proteasome Endopeptidase Complex
S Phase
Lysine
Chromatin
Half-Life
Intercellular Signaling Peptides and Proteins
Maintenance
Apoptosis
Breast Neoplasms

Keywords

  • ADA3
  • AKT
  • HAT complex
  • HER2
  • SAGA complex
  • acetylation
  • lapatinib
  • p300
  • phosphorylation
  • ubiquitination

ASJC Scopus subject areas

  • Molecular Biology
  • Developmental Biology
  • Cell Biology

Cite this

Epidermal Growth Factor Receptor activation promotes ADA3 acetylation through the AKT-p300 pathway. / Srivastava, Shashank; Mohibi, Shakur; Mirza, Sameer; Band, Hamid; Band, Vimla.

In: Cell Cycle, Vol. 16, No. 16, 18.08.2017, p. 1515-1525.

Research output: Contribution to journalArticle

Srivastava, Shashank ; Mohibi, Shakur ; Mirza, Sameer ; Band, Hamid ; Band, Vimla. / Epidermal Growth Factor Receptor activation promotes ADA3 acetylation through the AKT-p300 pathway. In: Cell Cycle. 2017 ; Vol. 16, No. 16. pp. 1515-1525.
@article{83f70c2f7a054f3f9d3a0abd2497da6f,
title = "Epidermal Growth Factor Receptor activation promotes ADA3 acetylation through the AKT-p300 pathway",
abstract = "The ADA3 (Alteration/Deficiency in Activation 3) protein is an essential adaptor component of several Lysine Acetyltransferase (KAT) complexes involved in chromatin modifications. Previously, we and others have demonstrated a crucial role of ADA3 in cell cycle progression and in maintenance of genomic stability. Recently, we have shown that acetylation of ADA3 is key to its role in cell cycle progression. Here, we demonstrate that AKT activation downstream of Epidermal Growth Factor Receptor (EGFR) family proteins stimulation leads to phosphorylation of p300, which in turn promotes the acetylation of ADA3. Inhibition of upstream receptor tyrosine kinases (RTKs), HER1 (EGFR)/HER2 by lapatinib and the accompanying reduction of phospho-AKT levels led to a decrease in p300 phosphorylation and ADA3 protein levels. The p300/PCAF inhibitor garcinol also destabilized the ADA3 protein in a proteasome-dependent manner and an ADA3 mutant with K→R mutations exhibited a marked increase in half-life, consistent with opposite role of acetylation and ubiquitination of ADA3 on shared lysine residues. ADA3 knockdown led to cell cycle inhibitory effects, as well as apoptosis similar to those induced by lapatinib treatment of HER2+ breast cancer cells, as seen by accumulation of CDK inhibitor p27, reduction in mitotic marker pH3(S10), and a decrease in the S-phase marker PCNA, as well as the appearance of cleaved PARP. Taken together our results reveal a novel RTK-AKT-p300-ADA3 signaling pathway involved in growth factor-induced cell cycle progression.",
keywords = "ADA3, AKT, HAT complex, HER2, SAGA complex, acetylation, lapatinib, p300, phosphorylation, ubiquitination",
author = "Shashank Srivastava and Shakur Mohibi and Sameer Mirza and Hamid Band and Vimla Band",
year = "2017",
month = "8",
day = "18",
doi = "10.1080/15384101.2017.1339846",
language = "English (US)",
volume = "16",
pages = "1515--1525",
journal = "Cell Cycle",
issn = "1538-4101",
publisher = "Landes Bioscience",
number = "16",

}

TY - JOUR

T1 - Epidermal Growth Factor Receptor activation promotes ADA3 acetylation through the AKT-p300 pathway

AU - Srivastava, Shashank

AU - Mohibi, Shakur

AU - Mirza, Sameer

AU - Band, Hamid

AU - Band, Vimla

PY - 2017/8/18

Y1 - 2017/8/18

N2 - The ADA3 (Alteration/Deficiency in Activation 3) protein is an essential adaptor component of several Lysine Acetyltransferase (KAT) complexes involved in chromatin modifications. Previously, we and others have demonstrated a crucial role of ADA3 in cell cycle progression and in maintenance of genomic stability. Recently, we have shown that acetylation of ADA3 is key to its role in cell cycle progression. Here, we demonstrate that AKT activation downstream of Epidermal Growth Factor Receptor (EGFR) family proteins stimulation leads to phosphorylation of p300, which in turn promotes the acetylation of ADA3. Inhibition of upstream receptor tyrosine kinases (RTKs), HER1 (EGFR)/HER2 by lapatinib and the accompanying reduction of phospho-AKT levels led to a decrease in p300 phosphorylation and ADA3 protein levels. The p300/PCAF inhibitor garcinol also destabilized the ADA3 protein in a proteasome-dependent manner and an ADA3 mutant with K→R mutations exhibited a marked increase in half-life, consistent with opposite role of acetylation and ubiquitination of ADA3 on shared lysine residues. ADA3 knockdown led to cell cycle inhibitory effects, as well as apoptosis similar to those induced by lapatinib treatment of HER2+ breast cancer cells, as seen by accumulation of CDK inhibitor p27, reduction in mitotic marker pH3(S10), and a decrease in the S-phase marker PCNA, as well as the appearance of cleaved PARP. Taken together our results reveal a novel RTK-AKT-p300-ADA3 signaling pathway involved in growth factor-induced cell cycle progression.

AB - The ADA3 (Alteration/Deficiency in Activation 3) protein is an essential adaptor component of several Lysine Acetyltransferase (KAT) complexes involved in chromatin modifications. Previously, we and others have demonstrated a crucial role of ADA3 in cell cycle progression and in maintenance of genomic stability. Recently, we have shown that acetylation of ADA3 is key to its role in cell cycle progression. Here, we demonstrate that AKT activation downstream of Epidermal Growth Factor Receptor (EGFR) family proteins stimulation leads to phosphorylation of p300, which in turn promotes the acetylation of ADA3. Inhibition of upstream receptor tyrosine kinases (RTKs), HER1 (EGFR)/HER2 by lapatinib and the accompanying reduction of phospho-AKT levels led to a decrease in p300 phosphorylation and ADA3 protein levels. The p300/PCAF inhibitor garcinol also destabilized the ADA3 protein in a proteasome-dependent manner and an ADA3 mutant with K→R mutations exhibited a marked increase in half-life, consistent with opposite role of acetylation and ubiquitination of ADA3 on shared lysine residues. ADA3 knockdown led to cell cycle inhibitory effects, as well as apoptosis similar to those induced by lapatinib treatment of HER2+ breast cancer cells, as seen by accumulation of CDK inhibitor p27, reduction in mitotic marker pH3(S10), and a decrease in the S-phase marker PCNA, as well as the appearance of cleaved PARP. Taken together our results reveal a novel RTK-AKT-p300-ADA3 signaling pathway involved in growth factor-induced cell cycle progression.

KW - ADA3

KW - AKT

KW - HAT complex

KW - HER2

KW - SAGA complex

KW - acetylation

KW - lapatinib

KW - p300

KW - phosphorylation

KW - ubiquitination

UR - http://www.scopus.com/inward/record.url?scp=85026757133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026757133&partnerID=8YFLogxK

U2 - 10.1080/15384101.2017.1339846

DO - 10.1080/15384101.2017.1339846

M3 - Article

C2 - 28759294

AN - SCOPUS:85026757133

VL - 16

SP - 1515

EP - 1525

JO - Cell Cycle

JF - Cell Cycle

SN - 1538-4101

IS - 16

ER -